Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial.

Bode, B W; Buse, J B; Fisher, M; Garg, S K; Marre, M; Merker, L; Renard, E; Russell-Jones, D L; Hansen, C T; Rana, A; Heller, S R

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial.

Bode, B W; Buse, J B; Fisher, M; Garg, S K; Marre, M; Merker, L; Renard, E; Russell-Jones, D L; Hansen, C T; Rana, A; Heller, S R.

Affiliation

Bode BW; Atlanta Diabetes Associates, Atlanta, GA, USA.

Diabet Med ; 30(11): 1293-7, 2013 Nov.

Article in En | MEDLINE | ID: mdl-23710902

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 1 / Insulins / Hypoglycemic Agents Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Female / Humans / Male Language: En Journal: Diabet Med Journal subject: ENDOCRINOLOGIA Year: 2013 Document type: Article Affiliation country: Country of publication:

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google